The NHS is on track to miss out on savings of over a billion pounds as patents for a new lineup of 85 biologics are set to expire within the next five years,
the British Generic Manufacturers Association has revealed in its new study.
The government's Voluntary Scheme for Branded Medicines Pricing and Access is expected to lead to a cost of more than £1 billion for the NHS in the coming years.
The BGMA research found that more than 85 biological medicines will experience loss of exclusivity during the upcoming VPAS Scheme period from 2024 to 2028.
"This includes blockbuster products like the cancer medicine Keytruda and wet macular product Eylea, which together generate approximately $25 billion in global
sales," BGMA said. "The molecules coming off-patent also cover other disease areas including oncology, diabetes, arthritis, and asthma."
While biological medicines dominate the medicines budget, constituting the largest cost and cost growth sectors, NHS England aims to expedite biosimilar
availability, yielding substantial savings and expanding patient access to vital treatments. Yet, the report found that "this is jeopardised by the influence of
the VPAS Scheme".
The Medicines and Healthcare products Regulatory Agency's (MHRA) Criminal Enforcement Unit (CEU) has seized a quantity of suspected unlicensed medical
products including unlicensed versions of Botox, numbing agents and dermal fillers in Bolton, Greater Manchester.
Officers from the MHRA and Greater Manchester Police conducted a raid across nine addresses in Bolton, Westhoughton and Leigh in the early hours of Thursday
13 July 2023, where two women and a man were arrested.
Andy Morling, MHRA Deputy Director of Criminal Enforcement said: "Medicines like these are powerful and dangerous in the wrong hands, potentially leading to
serious adverse health consequences. The criminals trading in these products are not only breaking the law, they also have no regard for your safety.
It is illegal to advertise, sell or supply medicines such as these without the appropriate authorisation. If you see these products, or any other powerful
medicines, being sold on social media or elsewhere online, think. It's unlikely to be legitimate. You can help the MHRA take action by reporting concerns
to us through our Yellow Card scheme.
The British Generic Manufacturers Association has backed the UK government's proposed changes to the Statutory Scheme for branded medicines, which includes
a 'Life Cycle Adjustment' (LCA) mechanism to permit a lower rebate rate for medicines sold in competitive markets. The association underscored the necessity for
crucial amendments to forestall unintended consequences and ensure a practical alignment with market operations.
A precisely tailored approach is crucial in ensuring sustainability and growth in this sector, the BGMA said in a statement on Oct. 11. The Department of Health
and Social Care is currently working on the successor to the 2019 voluntary scheme for branded medicines and pricing access (VPAS) agreement, slated to end in 2023.
Negotiations for this successor, scheduled to begin on January 1, 2024, are already underway.
"We are pleased that the Statutory Scheme consultation recognises that branded generic and biosimilar medicines are subject to different market dynamics and
competitive pressures," said Mark Samuels, Chief Executive of BGMA. "As such, a one-size-fits-all approach across all branded products is not suitable for the
next five years. It is crucial to adopt a precisely tailored approach to this sector, ensuring both sustainability and growth."
The Manchester Crown Court on Friday (9 December) sentenced three men, Cleave Lewis (35) and brothers, Denis Sutherland (58) and David Sutherland (59), to a
total of three years in jail after they pleaded guilty to the illegal sale and supply online of prescription-only medicines and controlled Class B and Class C
drugs, worth more than £1.5m.
They were found in possession of nearly 1.3m tablets of prescription-only drugs, including powerful sleeping pills, painkillers and anti-anxiety meds, when officers
from the Medicines and Healthcare products Regulatory Agency (MHRA) and Greater Manchester Police searched their residential homes and business premises in October
2017.
Following investigations by the agency, they also pleaded guilty to illegally making these medicines available online on three different websites for the public to
purchase without prescriptions.
The officials also recovered controlled medicines, over half a million (525,737) erectile dysfunction, slimming and herbal tablets, with an estimated value of
approximately £500k, from them.
After I have finished playing some casino games, using my, Juicy Stakes Casino bonuses, I am hungry. What should I eat? A juicy steak (wink, wink)? Fried
chicken? An Ingestible Pill? Wait, what? What is an ingestible pill? Is that a food or vitamin? Actually, it is neither.
It is new technology developed by Pfizer. Pfizer is the pharmaceutical company that gave us the COVID vaccines that do not provide lifetime immunity to COVID or
even prevent you from getting it in the short term. Pfizer is also the company that created the COVID medicine Paxlovid, which cause Biden to get a rebound COVID
right after he supposedly recovered from COVID.
Ingestible Pills are a version of a digital pill
A digital pill is also known as a smart pill or an ingestible sensor. It is a pharmaceutical dosage form that contains an ingestible sensor inside of a pill. The
sensor begins transmitting medical data after it is consumed.
This pill and its other related technology are considered Digital Medicine. The purpose of the sensor is to determine if a person is taking their medicine or they
are not taking their medicine. In other words, is the patient complying with taking their medicine or are they not complying with taking their medicine?
We cannot deny the benefits and uses of regenerative medicines as they have been so in demand in recent times. One such effective medicine with a lot of
potential health benefits is BPS-157. The peptide is thought to be extremely beneficial for those struggling with various neurological or health issues.
Another medicine with the same beneficial effects is the Semax peptide. Well, the benefits of both these peptide-based medicines and their other aspects will be
discussed in detail in this blog along with answering your question about the BPC-157 buy, Semax effects, and polypeptide.
ALL ABOUT BPC-157:
BPC-157, a pentadecapeptide consisting of 15 amino acids, is a synthetic peptide that is known for its positive effects on the human body. The peptide is derived
from human gastric juice. A protein is present in the human gastric juice through which this peptide is derived and synthesized. It is called a Body Protection
Protein as it exerts several therapeutic effects on the human body.
Not only have health benefits or therapeutic effects, the peptide has healing and regeneration powers. It also helps in the preventing formation of gastric ulcers.
This peptide is of great interest to researchers due to its numerous positive effects and benefits.
DOSING LEVELS OF BPC-157:
Not much about the dosing levels of BPC-157 has been researched yet but always try to concern the relevant persons before taking the medicine. The dosage
of BPC-157 depends on the health and body conditions of the person taking it along with other related factors.
The National Pharmacy Association (NPA)'s Health Education Foundation (HEF) has funded a major study that aimed to test the SPUR tool and evaluate how effective
it was at measuring medicines adherence.
The study has been published in the British Medical Journal Open.
Dr Joshua Wells, a fourth year PhD candidate at Kingston University, who was awarded the NPA bursary, was the lead researcher for the SPUR UK study, under the
guidance of Professor Reem Kayyali.
Created by Observia, a health research group, SPUR is a self-assessment questionnaire which helps to detect a patient's risk of medicine non-adherence and aims to
accurately articulate the reasons for health behaviour.
As well as funding from HEF, the study was made possible via a partnership with Kingston University and Kingston Hospital.
HEF chair of Trustees, Dr Ian Cubbin, said: "We are delighted that NPA's Health Education Foundation has played a part in such an important study. This research could
lead ultimately to a far more personalised, tailored approach to medicines optimisation - recognising that people's medicines behaviour can be highly individual to
them."
The NHS claims that it's been able to save taxpayers £1.2 billion in just three years by procuring hundreds of hospital medicines at a better price.
The adoption of cheaper versions of a single drug - adalimumab - which is used to treat more than 45,000 patients with rheumatoid arthritis, inflammatory bowel
disease and psoriasis, has accounted for about one third of the savings.
After the exclusive patent on the drug - originally known as its brand name Humira - expired in 2018, the NHS struck cost-saving deals to bulk-buy generic versions,
which have the same quality, safety and efficacy of a branded one.
Since then, tens of millions of pounds have been saved by buying cheaper generic versions of other medicines for conditions ranging from severe skin infections to
aggressive blood cancers.
Four in five medicines prescribed in the NHS are now non-branded, helping the NHS to achieve significant savings while ensuring the continuity of high-quality
patient care.
NHS chief executive Amanda Pritchard said: "Smart deals by the NHS mean patients are getting the best medicines and taxpayers are getting best value.
Almost nine in ten community pharmacists in England say they have patients who sometimes go without prescription medicines because they cannot afford the
prescription charge levied by the government.
Sixty-eight per cent of pharmacists in a National Pharmacy Association (NPA) survey, conducted via email in June 2022, said this has become more frequent in the
past year - suggesting that the rising cost of living could be leading more people to miss out on vital medicines.
While prescription charge does not apply in Scotland, Wales and Northern Ireland, in England an NHS patients needs to pay £9.35 per item. For patients who need
multiples medicines the cost could be exponential and virtually unaffordable amid rising inflation and higher cost of living.
The survey found that 89 per cent of pharmacies in England have patients who sometimes go without prescription medicines due to cost.
For most pharmacists (74 per cent) this happens one to five times a week. Fifteen per cent said they see such patients from six to 20 times a week.
A report released by the Independent Commission has blamed Brexit supply issues for medicine shortages.
NHS is forced to pay extortionate prices to fulfil the demand for vital antibiotics, anti-depressants, Attention Deficit Hyperactivity Disorder (ADHD), and
Hormone Replacement Therapy (HRT) drugs.
The report highlights the impact of affected medicine supply issues on community pharmacies and patients.
Janet Morrison, the chief executive of Community Pharmacy England, backed the report and said that the "medicine shortages and market instability appear to be
as bad as they have ever been".
She also explained how the Ukraine conflict, the COVID-19 pandemic, and broader economic instability also play a major factor in the situation.
The British Generic Manufacturers Association (BGMA) has raised concerns over the rise in the VPAS rate for 2023 to 26.5 per cent.
The Department of Health Social Care (DHSC) today announced that the 2019 voluntary scheme payment percentage for 2023 will be 26.5%. The 2019 voluntary scheme
for branded medicines pricing and access is an agreement between the Department of Health and Social Care, NHS England and the Association of the British
Pharmaceutical Industry.
BGMA believes that the high VPAS tax for 2023 risks more medicines shortages, rising prices for the NHS via reduced competition, and new medicine launches to the
UK being deferred.
Mark Samuels, Chief Executive of BGMA, said: "Raising the VPAS tax to 26.5% will damage the UK's medicines supply because it will make some products lossmaking. It
is more than a five-fold tax increase from 2021, and no industry can cope with this unpredictable and exceptional tax volatility.
The Department of Health and Social Care (DHSC) has allowed pharmacists to supply alternative penicillin to treat Strep A. It has issued Serious Shortage
Protocols (SSPs) for three penicillin medicines.
"The SSPs will help mitigate local supply issues of oral penicillin and allow pharmacists to supply alternative forms of the medicine if they do not have the
specific formulation stated on the prescription," said DHSC.
SSPs have been issued across the UK for 3 penicillin medicines on Thursday (December 15.
"Issuing an SSP allows pharmacists to legally supply a specified alternative medicine, removing the need for the patient to return to the prescriber - which saves
time in GP practices and inconvenience for patients."
"Demand for penicillin has risen recently as it is used to treat strep A and scarlet fever, and the increased demand means that some pharmacists are experiencing
temporary and localised supply issues and may not have the specific formulation listed on the prescription."
Medicinal mushrooms like shiitake & maitake mushrooms contain various health benefits. See how Asian medicinal mushrooms control high blood pressure and blood sugar levels in humans.
The Equality Act (which replaced the Disability Discrimination Act in 2010) is often cited as a reason for supplying medicines in a compliance aid. This is a complex piece of legislation, but, in essence, provides a statutory duty on businesses to make "reasonable adjustments" in relation to the service that they provide to take into account any relevant disability of a service-users.
This statutory obligation might include the provision of a compliance aid where a patient would be at a "substantial disadvantage" without. However, the need to provide medicines in a compliance aid under the Equality Act needs careful consideration and is a balancing exercise.
The NHS Terms of Service for community pharmacies in England state that medicines should be provided in original packs save in certain circumstances, which include because of patient needs.
Suboxone is a drug like heroin used to treat opioid dependence. It's an opioid based medicine.Taking Suboxone in high quantities can be very harmful. If someone takes it in such a quantity that someone would take it with medicine, then it can be dangerous for him to do so. It is used in the United States to quit opioid addiction.Many people use it to get relief from chronic pain but it is harmless. Low dose medicines are taken for chronic pain. Like every medicine, this medicine also has side effects like back pain, insomnia, Tongue pain, excessive sweating, vomiting, headache, and minor ailments.Suboxone is a drug made from an illegal drug, so do not take it without the advice of a doctor, it can be harmful to health.
Suboxone is a drug like heroin used to treat opioid dependence. It's an opioid based medicine.Taking Suboxone in high quantities can be very harmful. If someone takes it in such a quantity that someone would take it with medicine, then it can be dangerous for him to do so. It is used in the United States to quit opioid addiction.Many people use it to get relief from chronic pain but it is harmless. Low dose medicines are taken for chronic pain. Like every medicine, this medicine also has side effects like back pain, insomnia, Tongue pain, excessive sweating, vomiting, headache, and minor ailments.Suboxone is a drug made from an illegal drug, so do not take it without the advice of a doctor, it can be harmful to health.
The High Court has dismissed the British Generic Manufacturers Association (BGMA)'s claim on being excluded from ongoing negotiations between the government
and industry to agree a new Voluntary Scheme for medicine pricing and access (VPAS).
The association had sought a judicial review of the Department of Health and Social Care's (DHSC) decision to negotiate a new Voluntary Scheme for branded medicines
with the Association of the British Pharmaceutical Industry (ABPI) in April.
Commenting on the result of the case, Richard Torbett, Chief Executive of the ABPI said: "For over 60 years the ABPI has acted as the representative industry body
for negotiations on the Voluntary Scheme for branded medicines - a responsibility we take extremely seriously - and one which has been reaffirmed by today's
judgment.
"While we were disappointed that the BGMA decided to take this action - we recognise their decision was driven by the extreme challenge placed on all parts of the
industry from the surge in the branded medicine payment rates.
"The solution to these problems must be a completely new and sustainable approach to medicines provision in the UK which rapidly brings industry revenue payments in
line with comparator countries to unlock investment and growth."
Following Community Pharmacy England's Parliamentary drop-in event on medicines supply issues last week, several MPs have since raised questions to the Health
Secretary during a Health Questions session on July 18th.
According to CPE, MPs from all Parties displayed great engagement with the current pressures facing community pharmacies, particularly regarding medicines supply
issues.
During last week's event, Mike Amesbury, the MP for Weaver Vale, was present and directed a question to the Health Secretary: "Eighteen community pharmacists in my
constituency are reporting challenges with medicine supplies. What further actions will the Minister take to address and resolve this situation effectively?"
In response, Health Secretary Steve Barclay MP stated, "We have a dedicated team in the Department that focuses on medical supplies, which are an ongoing concern.
Challenges in this area are a routine part of our business."
The NHS Confederation and the Association of the British Pharmaceutical Industry (ABPI) has published a report that demonstrated the importance of the
collaboration between industry and the NHS to improve patient outcomes across the UK.
Analysis from the report has shown a significant variation in access to innovative medicines for patients across the UK and showed that uptake of new treatments
in these areas continues to be below the average of similar countries in Europe.
The report, 'Transforming Lives, Improving Health Outcomes', has highlighted four initiatives where effective partnerships between the NHS, patient organisations
and industry have helped to tackle unwarranted variation in the uptake of innovative medicines.
Transforming Lives, Improving Health Outcomes also called for a systemwide secondary prevention strategy covering all parts of the health system creating a barrier
to wider and consistent uptake of innovative medicine. It also noted that newly created Integrated Care Systems have the potential to improve preventative treatment.
The report data also showed a 51% variation of uptake of three types of medicines related to diabetes between NHS Trusts in England.
Insuman Comb 50 100units/ml suspension for injection 3ml cartridges has been discontinued with stocks being exhausted imminently, notified Department of Health
and Social Care (DHSC).
The department has issued a medicine supply notification for Insulin isophane biphasic human 50/50 (Insuman Comb 50) 100units/ml suspension for injection 3ml
cartridge.
"Humolog Mix 50 remains available, as do other biphasic insulin preparations, and the manufacturers can support a full uplift in supply," said DHSC.
A copy of this medicine supply notification, including further information, has been sent to all pharmacy NHS email addresses.
DHSC and NHSE/I's newly launched online Medicines Supply Tool provides up to date information about medicine supply issues. The contents of these MSNs can now be
viewed on the Tool.
The recent announcement that Royal Mail will be partnering with distance selling pharmacy (DSP) giant pharmacy2U highlights how standards of regulatory
enforcement are being ignored to accommodate the DSP model.
The brunt of these double standards hinges around the levelling down of temperature enforcement standards by the Medicines and Healthcare products Regulatory
Agency (MHRA) which demands mapping must be audited from the point of dispensing to the patient.
The MHRA has a well recognised duty to ensure medicines reach patients in a safe condition. The current anomaly appears to turn a blind eye to this step in the
supply chain at the point the wholesaler releases goods to the pharmacy hub.
Equally the training on delivering medicines safely and effectively direct to patients should apply fully to all hubs including DSPs. Why is it that DSPs are being
treated differently to bricks and mortar pharmacies? It's essentially the same patients receiving the same medicines from the same wholesalers.
A further regulatory disparity exists around how parcels must be "tracked and signed for" to be reasonably certain medicines are delivered into the hand of the
intended recipient, as per existing regulations.
Clearly an untracked, unsigned package cannot be guaranteed to finish in the hands of the intended recipient.
There is a very real possibility that such omission could lead to community pharmacy closures which will, in turn, lead to unemployment and a reduction in the
care services. At a time when integrated care systems have just gone live, the removal of vital support services leading to further inequalities is the wrong
message for both providers and patients alike.